newsfilter
← Earnings
Earnings Releases·

CorMedix Therapeutics — Third Quarter 2026 Earnings Summary

CorMedix Therapeutics reported approximately $355 million in cash and cash equivalents as of September 30, 2026. The company reaffirmed its full-year 2026 total revenue guidance of between $325 million and $345 million. Following the CMS release of the 2027 ESRD PPS final rule, the DefenCath post-TDAPA Add-on for Q1 2027 is set at $8.32 per dialysis session. CorMedix anticipates the Add-on rate will decline in Q2 2027 before rising in Q3 and Q4, with the average 2027 rate expected to exceed twice the current rate of $2.37.

Company
CORMEDIX INC
Sector
Healthcare
Industry
Biotechnology